Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC

MLA

Hochmair, M., et al. Updated Efficacy and Safety Results from ALTA, a Randomized Phase 2 Trial of Brigatinib in Crizotinib-Refractory ALK plus NSCLC. Jan. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..14a4e52a8201d69c462c533cfb0be9fd&authtype=sso&custid=ns315887.

APA

Hochmair, M., Ahn, M.-J., Camidge, D. R., Tiseo, M., Reckamp, K., Hansen, H. K., Kim, S.-W., Huber, R., West, H., Groen, H., Leighl, N., Gettinger, S., Langer, C., Paz-Ares Rodriguez, L., Smit, E., Kim, E., Reichmann, W., Kerstein, D., & Kim, D.-W. (2018). Updated efficacy and safety results from ALTA, a randomized phase 2 trial of brigatinib in crizotinib-refractory ALK plus NSCLC.

Chicago

Hochmair, M., M-J Ahn, D. R. Camidge, M. Tiseo, K. Reckamp, Holmskov K. Hansen, S-W Kim, et al. 2018. “Updated Efficacy and Safety Results from ALTA, a Randomized Phase 2 Trial of Brigatinib in Crizotinib-Refractory ALK plus NSCLC,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..14a4e52a8201d69c462c533cfb0be9fd&authtype=sso&custid=ns315887.